In order to characterize the expression profile of CP CML LSCs and identify potential therapeutic targets unique to this population, we sorted CD34+CD38+ and CD34+CD38−ALDHhigh cells to obtain highly enriched populations of progenitor and stem cells, respectively, from bone marrow of both healthy donors and CP CML patients (Figure 1A; Supplementary Table 1). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.